JAN 09, 2018 8:09 AM PST

Can A Diabetes Drug Treat Alzheimer's Disease?

Alzheimer's disease (AD) is called "The Long Goodbye" because it doesn't kill patients quickly, but over time, sometimes decades. It's a myth that Alzheimer's is not fatal. While many patients die from other causes while they have the disease, AD destroys brain tissue, and the result is a progressive loss of bodily functions and eventually death. 

There is currently no cure for Alzheimer's which is why hundreds of research studies are ongoing to uncover more about how it starts, how it progresses and how it might be stopped. Estimates from the WHO and the CDC show that nearly 15 million Americans suffer from the disorder and worldwide that number jumps to more than 44 million. The numbers are going nowhere but up, and it's become a global health concern.

New research into a drug that was developed to treat Type 2 diabetes is being hailed as a possible treatment for AD after a clinical trial showed that it "significantly reversed memory loss" in lab mice. The study, led by Professor Christian Holscher of Lancaster University in the UK, was funded in part by the Alzheimer's Society. Dr. Doug Brown, Director of Research and Development for the society stated, "With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer's. It's imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer's and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them."

The drug tested is what's called a "triple receptor agonist." In diabetes, the body cannot process glucose correctly. Cells become resistant in insulin and patients must take additional insulin to avoid dangerously high blood glucose levels. Triple receptor agonists allow three factors, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon, to penetrate cells and be used by the body for fuel instead of building up in the blood. Diabetes and Alzheimer's are related in that some patients with AD have impaired signaling in the brain pathways that carry these three growth factors. Other research studies have shown that drugs for diabetes, particularly liraglutide, have shown memory benefits in patients with dementia.

To conduct the study, the team used lab mice that had been genetically altered to carry a version of the same genes that humans with an inherited form of AD have. The mice were taught how to navigate through a maze that involved remembering specific tasks and directions. The mice who were given the drug showed significant improvement in getting through the maze. Examinations also revealed there was less build-up of amyloid plaques in the brain, reduced inflammation and oxidative stress on brain cells and increased amounts of a growth factor that protects cell function.

Professor Holscher explained, "These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro- protective effects in several studies." Check out the video below to learn more about this diabetes drug which could be the sweetest thing for an entirely different group of patients.

Sources: Lancaster University, via EurekAlert!, The Big Think, Journal article, Brain Research 

About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
SEP 21, 2020
Neuroscience
Scientists Compare Structural and Functional Evolution with First Atlas of Cavefish Brains
SEP 21, 2020
Scientists Compare Structural and Functional Evolution with First Atlas of Cavefish Brains
Cavefish are fish that dwell in caves, unable to access the outside world. Often, they were separated from their closest ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 07, 2020
Neuroscience
Researchers Discover Molecular Mechanism for Memory Formation
OCT 07, 2020
Researchers Discover Molecular Mechanism for Memory Formation
Researchers from MIT have found that when the brain forms a new memory, neurons known as 'engram cells' encode t ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
OCT 07, 2020
Neuroscience
Biocompatible Gel Restores Sciatic Nerve Function in Rats
OCT 07, 2020
Biocompatible Gel Restores Sciatic Nerve Function in Rats
Video: Explains poly(lactic-co-glycolic acid), a hydrogel biopolymer that is a similar concept to the new hydrogel built ...
NOV 08, 2020
Neuroscience
Psychedelic DMT Improves Memory by Neurogenesis
NOV 08, 2020
Psychedelic DMT Improves Memory by Neurogenesis
Researchers from the Complutense University of Madrid in Spain have found that dimethyltryptamine (DMT), the psychoactiv ...
Loading Comments...